Navigation Links
Accuray Reports Financial Results for First Quarter of Fiscal Year 2014
Date:11/7/2013

GAAP net loss with a non-GAAP measure of adjusted EBITDA. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the Company and facilitates a more meaningful comparison of results for current periods with previous operating results.  Additionally, it will assist management in analyzing future trends, making strategic and business decisions and establishing internal budgets and forecasts. A reconciliation of non-GAAP adjusted EBITDA to GAAP net loss (the most directly comparable GAAP measure) is provided in the schedule below.

There are limitations in using this non-GAAP financial measure because it is not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  This non-GAAP financial measure should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP and the reconciliations of the non-GAAP financial measure provided in the schedule below.

About AccurayAccuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor StatementStatements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities L
'/>"/>

SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Acquisitions, Clinical Trial Results, Date Extensions and Financial Results - Research Report on Endo, Astex, Auxilium, Accuray, and BioScrip
2. Accuray Announces First CyberKnife System in South America
3. Accuray Surpasses 600 Installations Globally
4. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
5. Omeros Corporation Reports Third Quarter 2013 Financial Results
6. Global Positron Emission Tomography Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at MarketResearchReports.biz
7. Global In Vitro Fertilization Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at MarketResearchReports.biz
8. Global Biophotonics Market & OSS BSS Industry 2012-2016 Reports
9. China Vanadium Catalyst Market for Sulfuric Acid Production in A New Research Available at MarketReportsChina.com
10. Cytos Biotechnology Ltd Reports Third Quarter 2013 Financial Results and Recent Developments
11. Neurocrine Biosciences Reports Third Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Physicians Choice Laboratory Services (PCLS) ... which enables healthcare providers to individualize therapeutic treatments ... results, healthcare providers are better able to assess ... minimizing risks for adverse drug reactions and interactions. ... FDA [1] more than 2.2 million adverse drug ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... Convey Computer , the leader in hybrid-core ... University won first place in the 2014 MemoCODE ... team’s solution achieved the highest overall performance in the ... finisher. , Experts from all segments of the commercial ... using a variety of design tools, hardware and software. ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... March 4 Vermillion, Inc.,(Nasdaq: VRMLD ), ... its diagnostic test programs and provided a preview,of ... the course of 2008. The,Company also released financial ... 31, 2007., "In 2007, Vermillion made significant ...
... p.m. Central European/5:30 a.m. Pacific Time,members of Cell Therapeutics, Inc.,s (CTI) (Nasdaq: CTIC ... recent,transactions targeting cleaning up the capital structure, and upcoming,product and sales milestones., ... Conference Call Numbers ... Wednesday, March 5 ...
... Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) ... exhibit CT Laser Mammography (CTLM(R)),technology at the annual ... in Vienna, Austria. IDSI will be located at ... ), "We are pleased to be a ...
Cached Biology Technology:Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 2Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 3Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 5Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 6Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 7Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 8Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 9Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones 2CT Laser Mammography Technology to be Featured at European Congress of Radiology 2
(Date:10/15/2014)... Gauß-Allianz has admitted Johannes Gutenberg University Mainz (JGU) ... science hub continues to maintain a significant nationwide ... , "The acceptance of Johannes Gutenberg University Mainz ... a milestone in the national and international competition ... state of Rhineland-Palatinate can be proud that Mainz ...
(Date:10/15/2014)... 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market releases photos and video of ... on Monday October 13 th . Gino ... and angel investor Mr. Chad A. Verdi rang ... NXT-ID thanked his investors and employees "for their work and dedication ...
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
... The ribosome can be thought of as a decryption device ... genetic code, which is delivered in the form of messenger ... of amino acids. The final assembly of amino acids into ... Without ribosomes, a cell would be unable to produce any ...
... question that can make or break their chances at reproducing: does ... Researchers from The University of Manchester and Syracuse University ... that where animals fall on the lover/fighter scale depends on how ... In species where fighting for the right to mate ...
... 2014 - Eurofins MWG Operon, a leader in ... sequencing services with the Ion Proton Next Generation ... sequencing was also awarded after joining Life Technologies ... program. Membership in Life Technologies, CSP program is ...
Cached Biology News:Mitochondrial ribosome revealed 2Mitochondrial ribosome revealed 3Mitochondrial ribosome revealed 4Does it pay to be a lover or a fighter? It depends on how you woo females 2
... instrument is the most advanced thermal cycler ... thermal performance, the Dyad also boasts graphical ... point-and-click navigation via touch pad or mouse. ... and economically expanded to a four-bay system ...
... Pierce ready-to-use 2-D gel marker mix was designed ... gel marker mix contains a complement of seven ... of value to those who use markers to ... molecular weight values of proteins undergoing 2-D separation ...
... Tetrad 2 thermal cycler is a completely ... Tetrad chassis, and it accepts the full ... delivers the same precision in thermal performance ... Tetrad thermal cyclers, allowing easy transport of ...
... Engine Tetrad thermal cycler expands the ... PTC-200 DNA Engine cycler. ... with a footprint only twice the ... laboratories that run massive quantities of ...
Biology Products: